COVID-19 RAPID ANTIGEN SALIVA PEN TEST

Quantity available	100- 1,999 Units	2,000-4999 Units	5,000-9,999 Units	10k - 50 k Units	50k - 100k Units
	AUD inc gst	**AUD inc gst**	**AUD inc gst**	**AUD inc gst**	**AUD inc gst**
Per unit/pen	$14.80	$14.00	$12.75	POA	POA
20 pens per box, price per box	$296.00	$280.00	$255.00		
27 boxes per carton (540 tests)	$7992.00	$7560.00	$6885.00		
MOQ is 100 units/pens. Delivery fees may apply					

Processing and compliance:
Step1: Decide the volume, scan and email the order to: poliveil@poliveil.com
Step 2: An invoice will be emailed back.
Step 3: Once the funds have been received the order will be dispatched.
NOTE: Under **no** circumstances can any product be returned. Once we fulfill this order, POLIVEIL no longer has a chain of custody over these TGA approved products. You MUST ensure you follow the directions/rules for use, and you MUST undertake, or nominate someone/ supervisor to undertake the training. By signing this order form I agree that I will complete the online training module at BOOK HERE as per the Terms and Conditions.

COMPANY DETAILS			
Company Name			
Company ABN			
Delivery Address			
Suburb		Postcode	

CONTACT DETAILS	
Contact Name	
Contact email	
Contact Phone	

ORDER DETAILS		
Order	QTY	Please note order is only processed on receipt of payment. Delivery fees apply based on order size.
Box of 20 units		
Carton of 540 units		

COMPANY ORDER AUTHORISATION	
Authorised Name	
Authorised Signature	
Date	

Poliveil is reseller on behalf of Emergence Technology.

Australian Government

Department of Health
Therapeutic Goods Administration

Australian Register of Therapeutic Goods Certificate

Issued to

Emergence Technology Pty Ltd

for approval to supply

Severe acute respiratory syndrome-associated coronavirus IVDs

ARTG Identifier	372335
ARTG Start Date	6/08/2021
Product Category	Medical Device Included - IVD Class 3
GMDN	CT772
GMDN Term	Severe acute respiratory syndrome-associated coronavirus IVDs
Intended Purpose	The COVID-19 Antigen Saliva Test Kit is an in vitro immunoassay. The assay is for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from saliva samples. Negative results do not preclude SARS-CoV-2 viral infection. Testing results should not be the sole basis for treatment or other management decisions.